Drugs / Bimatoprost SR
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02247804 | Dec 2014 → Feb 2018 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-01-07 | AbbVie | Allergan Announces Positive 3-Month Topline Results from Second Phase 3 Study of Bimatoprost SR (Sustained-Release) Implant for Lowering Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension abbvie.com ↗ |
| 2018-06-13 | AbbVie | Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (Sustained-Release) Implant for IOP Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension abbvie.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bimatoprost SR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02247804 ↗ |
| Route | Other | “an intracameral, biodegradable, sustained-release bimatoprost implant” PMID 36378864 ↗ Nov 2022 |